🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,589 results for “Pharma” Clear

  1. Voclosporin

    Aurinia Pharmaceuticals

    Covid19

    phase 2 small molecule completed

    1 trial

  2. Voclosporin

    Aurinia Pharmaceuticals

    Kidney Diseases

    phase 2 small molecule completed

    1 trial

  3. Voclosporin

    Aurinia Pharmaceuticals

    Focal Segmental Glomerulosclerosis

    phase 2 small molecule terminated

    1 trial

  4. Voclosporin High Dose

    Aurinia Pharmaceuticals

    Lupus Nephritis

    phase 2 small molecule completed

    1 trial

  5. Voclosporin Ophthalmic Solution

    Aurinia Pharmaceuticals

    Dry Eye

    phase 2 small molecule completed

    1 trial

  6. Volixibat

    Mirum Pharmaceuticals International B.V.

    Primary Biliary Cholangitis

    phase 2 small molecule active

    1 trial

  7. Volixibat

    Mirum Pharmaceuticals International B.V.

    Primary Sclerosing Cholangitis

    phase 2 small molecule active

    1 trial

  8. Volixibat

    Mirum Pharmaceuticals International B.V.

    Intrahepatic Cholestasis of Pregnancy

    phase 2 small molecule terminated

    1 trial

  9. Vonafexor

    Lacuna Pharma Pty Ltd

    Alport Syndrome

    phase 2 small molecule active

    1 trial

  10. Vonafexor, ROSUVASTATIN , IOHEXOL , Vonafexor

    Lacuna Pharma Pty Ltd

    Impaired renal function and suspected MASH

    phase 2 small molecule active

    1 trial

  11. Vonoprazan

    Phathom Pharmaceuticals

    Eosinophilic Esophagitis

    phase 2 small molecule active

    1 trial

  12. Vosoritide Injection

    BioMarin Pharmaceutical Australia Pty Ltd

    Idiopathic Short Stature

    phase 2 small molecule active

    1 trial

  13. Vosoritide Injection

    BioMarin Pharmaceutical Australia Pty Ltd

    Noonan Syndrome

    phase 2 small molecule active

    1 trial

  14. Voxzogo 0.56 mg powder and solvent for solution for injection, Voxzogo 1.2 mg powder and solvent for solution for injection

    BioMarin Pharmaceutical Australia Pty Ltd

    Achondroplasia

    phase 2 small molecule active

    1 trial

  15. Voxzogo 0.56 mg powder and solvent for solution for injection, modified recombinant human C-type natriuretic peptide (rhCNP), Lyophilized powder for reconstitution, Voxzogo 1.2 mg powder and solvent for solution for injection

    BioMarin Pharmaceutical Australia Pty Ltd

    Idiopathic Short Stature (ISS)

    phase 2 small molecule active

    1 trial

  16. Voxzogo 0.56 mg powder and solvent for solution for injection, powder and solvent for solution for injection

    BioMarin Pharmaceutical Australia Pty Ltd

    Hypochondroplasia

    phase 2 small molecule active

    1 trial

  17. Voxzogo 1.2 mg powder and solvent for solution for injection, Voxzogo 0.56 mg powder and solvent for solution for injection, modified recombinant human C-type natriuretic peptide (rhCNP)

    BioMarin Pharmaceutical Australia Pty Ltd

    Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome

    phase 2 small molecule active

    1 trial

  18. WVE-006

    Elan Pharma International

    Alpha-1 antitrypsin deficiency (AATD)

    phase 2 small molecule active

    1 trial

  19. X-vivo 15 (serum-free growth medium manufactured under gmp and commercially available from Lonza)

    Biogen

    Peripherial arterial disease (PAD) & Chronic-Limb Threatening Ischemia (CLTI) patients who have not responded to standard pharmacological treatment or control of risk factors, and/or had a revascularisation with continued presence of smaller vessel (microvasculature) disease, and do not have the option of a revascularization treatment.

    phase 2 small molecule active

    1 trial

  20. X4P-001

    X4 Pharmaceuticals, Inc

    Clear Cell Renal Cell Carcinoma

    phase 2 small molecule completed

    2 trials

  21. X4P-001

    X4 Pharmaceuticals, Inc

    WHIM Syndrome

    phase 2 small molecule completed

    1 trial

  22. XEN1101 10 mg

    Xenon Pharmaceuticals

    Major Depressive Disorder

    phase 2 small molecule completed

    1 trial

  23. XEOMIN 100 unités, poudre pour solution injectable, Placebo of Xeomin 100 UI, powder for injection

    Pari Pharma GmbH

    Degenerative shoulder rotator cuff tendinopathy

    phase 2 small molecule active

    1 trial

  24. XEOMIN, 100 unità, polvere per soluzione iniettabile

    Verona Pharma Ireland Limited

    multifocal spasticity of the upper and lower limb due to cerebral palsy

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources